International Journal of Drug Delivery Technology
Volume 15, Issue 3

Comparative Study: Olanzapine and Lumateperone as Antipsychotic Drugs 

Vasudha S Bavadekar1*, Angha M Joshi1, Manasi Wagdarikar2, Keren Jadhav3, Pratiksha Khandare3 

1Department of Pharmaceutical Chemistry, SCES’s Indira College of Pharmacy, Tathawade, Pune-411033, India

1Savitribai Phule Pune University, Pune, Maharashtra, India

2Indira University’s School of Pharmacy, Pune, Maharashtra, India

3Department of Pharmacy Practice, Modern College of Pharmacy, Nigdi, Pune-411044, Maharashtra, India 

Received: 6th May, 2025; Revised: 13th Jul 2025; Accepted: 8th Aug, 2025; Available Online: 25th Sep, 2025 

ABSTRACT

A new antipsychotic drug called Lumateperone has shown promise in the treatment of bipolar disorder and schizophrenia. It works by modulating dopaminergic, serotonergic, and glutamatergic neurotransmission. One characteristic that sets this dual-acting drug apart from other antipsychotics is its intermediate affinity for D 2 receptors and high affinity for 5- HT2A receptors. According to clinical research, Lumateperone effectively reduces the symptoms of schizophrenia while having a relatively low risk of extrapyramidal symptoms and metabolic abnormalities. Notably, Lumateperone pharmacokinetic profile is characterized by extensive metabolism and low bioavailability, underscoring the significance of cautious dosage and possible medication interactions. Comparative research with the well-known antipsychotic Olanzapine has shown that Lumateperone is more tolerable and has a lower risk of weight gain and negative metabolic consequences. Clarifying Lumateperone effects on neurotransmitter systems and investigating for the clinical features of schizophrenia are two future research directions. The ultimate goal is precision medicine techniques that are adjusted to meet the needs of each patient. Lumateperone, with its distinct therapeutic profile and enhanced tolerability as antipsychotic drug.

Keywords: Lumateperone, Olanzapine, Comparative research, antipsychotic, pharmacokinetic profile

How to cite this article: Vasudha S Bavadekar, Angha M Joshi, Manasi Wagdarikar, Keren Jadhav, Pratiksha Khandare. Comparative Study: Olanzapine and Lumateperone as Antipsychotic Drugs. International Journal of Drug Delivery Technology. 2025;15(3):1417-25. doi: 10.25258/ijddt.15.3.65

REFERENCES

  1. Meftah AM, Deckler E, Citrome L, Kantrowitz JT. New Discoveries for an Old Drug: A Review of Recent Olanzapine Research. Postgraduate Medicine. 2020;132(1):80-90. DOI: 1080/00325481.2019.1701823
  2. Prommer E. Olanzapine: Palliative Medicine Update. American Journal of Hospice and Palliative Medicine. 2012;30(1):75-82. DOI: 1177/1049909112441241
  3. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine. Neuropsychopharmacology. 1996;14(2):87-96
  4. Elsayem A, Bush SH, Munsell MF. Subcutaneous Olanzapine for Hyperactive or Mixed Delirium in Patients with Advanced Cancer: A Preliminary Study. Journal of Pain and Symptom Management. 2010;40(5):774-82. DOI: 1016/j.jpainsymman.2010.02.024
  5. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: Pharmacokinetic and Pharmacodynamic Profile. Clinical Pharmacokinetics. 1999;37(3):177-93. DOI: 2165/00003088-199937030-00001
  6. Conley RR, Meltzer HY. Adverse Events Related to Olanzapine. The Journal of Clinical Psychiatry. 2000;61(8)(supplement 8):26-9; discussion 30. https://pubmed.ncbi.nlm.nih.gov/10811240
  7. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: An Updated Review of Its Use in the Management of Schizophrenia. Drugs. 2001;61(1):111-61. DOI: 2165/00003495-200161010-00011
  8. Matza LS, Baker TM, Revicki DA. Efficacy of Olanzapine and Ziprasidone for the Treatment of Schizophrenia: A Systematic Review. CNS Drugs. 2005;19(6):499-515. DOI: 2165/00023210-200519060-00003
  9. DePietro T. Lumateperone: A Truly Innovative Antipsychotic Medication? American Journal of Psychiatry Residents’ Journal. 2023;18(3):18-20. DOI: 1176/appi.ajp-rj.2023.180306
  10. Snyder GL, Vanover KE, Zhu H, et al. Functional Profile of a Novel Modulator of Serotonin, Dopamine, and Glutamate Neurotransmission. Psychopharmacology. 2015;232(3):605-21. DOI: 1007/s00213-014-3704-1
  11. Calabrese JR, Durgam S, Satlin A. Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. American Journal of Psychiatry. 2021;178(11):1098-106. DOI: 1176/appi.ajp.2021.20071006
  12. Jawad MY, Alnefeesi Y, Ceban F, et al. Lumateperone for the Treatment of Adults with Schizophrenia: A Systematic Review. Current Psychiatry Reports. 2022;24(8):359-68. DOI: 1007/s11920-022-01344-1
  13. Thomas K, Saadabadi A. Olanzapine. StatPearls Publishing, 2023. Available on: https://pubmed.ncbi.nlm.nih.gov/30422498/
  14. Kantrowitz JT, Citrome L. Olanzapine: Review of Safety 2008. Expert Opinion on Drug Safety. 2008 Nov;7(6):761-9. DOI: 1517/14740330802423234
  15. Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight Gain and Changes in Metabolic Variables Following Olanzapine Treatment in Schizophrenia and Bipolar Disorder. Clinical Drug Investigation. 2011;31(7):455-82. DOI: 2165/11589060-000000000-00000
  16. Detke HC, DelBello MP, Landry J, Hoffmann VP, Heinloth A, Dittmann RW. A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder. Journal of Child and Adolescent Psychopharmacology. 2016;26(10):922-34. DOI: 1089/cap.2016.0010
  17. Schulz C, Haight RJ. Safety of Olanzapine Use in Adolescents. Expert Opinion on Drug Safety. 2013;12(5):777-82. DOI: 1517/14740338.2013.815164
  18. Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A Commentary on the Efficacy of Olanzapine for the Treatment of Schizophrenia: The past, Present, and Future. Neuropsychiatric Disease and Treatment. 2019;15:2559-69. DOI: 2147/NDT.S209284
  19. McDonnell DP, Landry J, Detke HC. Long-Term Safety and Efficacy of Olanzapine Long-Acting Injection in Patients with Schizophrenia or Schizoaffective Disorder: A 6-Year, Multinational, Single-Arm, Open-Label Study. International Clinical Psychopharmacology. 2014;29(6):322-31. DOI: 1097/YIC.0000000000000038
  20. Kolli P, Kelley G, Rosales M, Faden J, Serdenes R. Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions. Pharmacogenomics and Personalized Medicine. 2023;16(1):1097-108. DOI: 2147/PGPM.S391401
  21. Cooper D, Lumateperone GV. StatPearls Publishing, 2023. Available on: https://www.ncbi.nlm.nih.gov/books/NBK560844/
  22. Greenwood J, Acharya RB, Marcellus V, Rey JA. Lumateperone: A Novel Antipsychotic for Schizophrenia. The Annals of Pharmacotherapy. 2021;55(1):98-104. DOI: 1177/1060028020936597
  23. Snyder GL, Vanover KE, Davis RE, Li P, Fienberg A, Mates S. A Review of the Pharmacology and Clinical Profile of Lumateperone for the Treatment of Schizophrenia. Advances in Pharmacology. 2021;90:253-76. DOI: 1016/bs.apha.2020.09.001
  24. Sowa-Kućma M, Pańczyszyn-Trzewik P, Jaeschke RR. Exploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic. International Journal of Molecular Sciences. 2024;25(24):13289. DOI: 3390/ijms252413289
  25. Correll CU, Vanover KE, Davis RE, Chen R, Satlin A, Mates S. Safety and Tolerability of Lumateperone 42 mg: An Open-Label Antipsychotic Switch Study in Outpatients with Stable Schizophrenia. Schizophrenia Research. 2021;228:198-205. DOI: 1016/j.schres.2020.12.006
  26. Correll CU, Davis RE, Weingart M, Saillard J, O’Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S, Vanover KE. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2020;77(4):349-58. DOI: 1001/jamapsychiatry.2019.4379
  27. Tarzian M, Ndrio M, Chique B, Serai J, Thalackal B, Lau J, Fakoya AO. Illuminating Hope for Mental Health: A Drug Review on Lumateperone. Cureus. 2023;15(9):e46143. DOI: 7759/cureus.46143
  28. Longo G, Cicolini A, Orsolini L, Volpe U. The Novel Antipsychotic Lumateperone (ITI-007) in the Treatment of Schizophrenia: A Systematic Review. Brain Sciences. 2023;13(12):1641. DOI: 3390/brainsci13121641
  29. Fulton B, Goa KL. Olanzapine A Review of Its Pharmacological Properties and Therapeutic Efficacy in the Management of Schizophrenia and Related Psychoses. Drugs. 1997;53(2):281-98. DOI: 2165/00003495-199753020-00007
  30. Wojtasik-Bakalarz K, Siwek M. New Antipsychotic Medication. Pharmacotherapy in Psychiatry and Neurology. 2023;39(1):19-38. DOI: 5114/fpn.2022.124608
  31. Syed AB, Brašić JR. The Role of Lumateperone in the Treatment of Schizophrenia. Therapeutic Advances in Psychopharmacology. 2021;11:20451253211034019. DOI: 1177/20451253211034019
  32. Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN. Novel Compounds in the Treatment of Schizophrenia: A Selective Review. Brain Sciences. 2023;13(8):1193. DOI: 3390/brainsci13081193
  33. Haddad PM, Correll CU. The Acute Efficacy of Antipsychotics in Schizophrenia: A Review of Recent Meta-analyses. Therapeutic Advances in Psychopharmacology. 2018;8(11):303-18. DOI: 1177/2045125318781475
  34. Lumateperone BHA. First Approval. Drugs. 2020;80:417-23. DOI: 1007/s40265-020-01278-5
  35. Stephenson CM, Pilowsky LS. Psychopharmacology of Olanzapine. A Review. The British Journal of Psychiatry. Supplement. 1999;(38):52-8. https://pubmed.ncbi.nlm.nih.gov/10884900
  36. Vyas P, Hwang BJ, Brašić JR. An Evaluation of Lumateperone Tosylate for the Treatment of Schizophrenia. Expert Opinion on Pharmacotherapy. 2020;21(2):139-45. DOI: 1080/14656566.2019.1695778
  37. Kaczmarek A, Szymajda W, Dettlaff K. Lumateperone in the Treatment of Psychiatric Disorders – A Review of the Literature. Pharmacotherapy in Psychiatry and Neurology. 2023;39(1):39-52. DOI: 5114/fpn.2023.127423
  38. Tazi A, Errachidi F, Sonawane D, Tahri G, Rao S, Mehta S. An Economic Model to Understand the Cost-Effectiveness of Olanzapine Orally Dispersible Tablets (ODT) and Olanzapine Film Coated Tablets as A Group Compared with Other Oral Atypical Antipsychotics for Treating Schizophrenia in Morocco. Annals of General Psychiatry. 2024 Sep 18;23(1). https://annals-general-psychiatry.biomedcentral.com/articles/10.1186/s12991-024-00516-y:33
  39. Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP. Reasons for Continuing or Discontinuing Olanzapine in the Treatment of Schizophrenia from the Perspectives of Patients and Clinicians. Patient Preference and Adherence. 2011;5:547-54. DOI: 2147/PPA.S23255
  40. Tollefson GD, Kuntz AJ. Review of Recent Clinical Studies with Olanzapine. The British Journal of Psychiatry. Supplement. 1999;174(37):30-5. https://pubmed.ncbi.nlm.nih.gov/10211139
  41. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO. Olanzapine: A Basic Science Update. The British Journal of Psychiatry. Supplement. 1999;(37):36-40. https://pubmed.ncbi.nlm.nih.gov/10211140
  42. Chue P, Chue J. A Review of Olanzapine Pamoate. Expert Opinion on Pharmacotherapy. 2012;13(11):1661-70. DOI: 1517/14656566.2012.686169
  43. Edinoff A, Wu N, deBoisblanc C et al. Lumateperone for the Treatment of Schizophrenia. Psychopharmacology Bulletin. 2020;50(4):32-59. https://pubmed.ncbi.nlm.nih.gov/33012872
  44. Kantrowitz JT. The Potential Role of Lumateperone – Something Borrowed? JAMA Psychiatry. 2020;77(4):343-4. DOI: 1001/jamapsychiatry.2019.4265
  45. Suppes T, Durgam S, Kozauer SG et al. Adjunctive Lumateperone (ITI‐007) in the Treatment of Bipolar Depression: Results from a Randomized Placebo-Controlled Clinical Trial. Bipolar Disorders. 2023;25(6):478-88. DOI: 1111/bdi.13310
  46. Mohamed W. In: Essential Guide to Neurodegenerative Disorders Mechanistic, Diagnostic and Therapeutic Advances Atypi. Cal Antipsychotic Lumateperone Beyond Schizophrenia: Seeking Clarity in A Time of Uncertainty. Elsevier, London. pp. 461-7